319 related articles for article (PubMed ID: 32974853)
1. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
Liu J; Deng YT; Jiang Y
Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib treatment in elderly patients with unresectable or metastatic soft tissue sarcoma: a retrospective study.
Zhang XY; Liu J; Deng YT; Jiang Y
Anticancer Drugs; 2022 Jan; 33(1):e519-e524. PubMed ID: 34282747
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of anlotinib in patients with unresectable or metastatic well-differentiated/dedifferentiated liposarcoma: a single-center retrospective study.
Li ZK; Liu J; Deng YT; Jiang Y
Anticancer Drugs; 2021 Feb; 32(2):210-214. PubMed ID: 33290314
[TBL] [Abstract][Full Text] [Related]
5. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.
Tian Z; Liu H; Zhang F; Li L; Du X; Li C; Yang J; Wang J
Invest New Drugs; 2020 Oct; 38(5):1559-1569. PubMed ID: 32100146
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
Chi Y; Fang Z; Hong X; Yao Y; Sun P; Wang G; Du F; Sun Y; Wu Q; Qu G; Wang S; Song J; Yu J; Lu Y; Zhu X; Niu X; He Z; Wang J; Yu H; Cai J
Clin Cancer Res; 2018 Nov; 24(21):5233-5238. PubMed ID: 29895706
[No Abstract] [Full Text] [Related]
7. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
[TBL] [Abstract][Full Text] [Related]
8. The real-world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post-ALTER0203 trial era.
Zhang RS; Liu J; Deng YT; Wu X; Jiang Y
Cancer Med; 2022 Jun; 11(11):2271-2283. PubMed ID: 35191609
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.
Wang HY; Chu JF; Zhang P; Wang JQ; Yan Z; Yao SN; Yao ZH; Liu YY
Onco Targets Ther; 2020; 13():1561-1568. PubMed ID: 32110053
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy.
Liu Y; Xiao Q; He J; Hu H; Du J; Zhu Y; Chen J; Liu Z; Wang J; Sun L; Xu D; Li J; Liao X; Wang J; Cai Y; Cai C; Jin Z; Wang L; Yuan Y; Ding K
BMC Med; 2022 May; 20(1):155. PubMed ID: 35513832
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib is effective in the treatment of advanced pancreatic cancer: a case report.
Li S; Niu M; Deng W; Li N; Wei C; Luo S
Anticancer Drugs; 2022 Jan; 33(1):e558-e561. PubMed ID: 34387586
[TBL] [Abstract][Full Text] [Related]
13. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.
Cai M; Zhu J; Zhou G
Comput Math Methods Med; 2022; 2022():3287961. PubMed ID: 35991143
[TBL] [Abstract][Full Text] [Related]
15. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
[TBL] [Abstract][Full Text] [Related]
16. Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy.
Cai J; Zhou S; Luo Y; Liu A
Medicine (Baltimore); 2021 Dec; 100(51):e28126. PubMed ID: 34941058
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial.
Lai S; Li P; Liu X; Liu G; Xie T; Zhang X; Wang X; Huang J; Tang Y; Liu Z; Shen G; Li C; Lu F; Wang L; Jiang F; Sun C; Chen Y; Chen M
Cancer Biol Med; 2024 Mar; 21(5):433-44. PubMed ID: 38445445
[TBL] [Abstract][Full Text] [Related]
18. Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial.
Xu B; Pan Q; Pan H; Li H; Li X; Chen J; Pang D; Zhang B; Weng D; Peng R; Fang M; Zhang X
EClinicalMedicine; 2023 Oct; 64():102240. PubMed ID: 37767191
[TBL] [Abstract][Full Text] [Related]
19. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.
Su H; Yu C; Ma X; Song Q
Invest New Drugs; 2021 Oct; 39(5):1411-1418. PubMed ID: 33765213
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study.
Li L; Zhang H; Xie Y; Su N; Su S; Zhang X; Cen W
Comput Math Methods Med; 2022; 2022():1475871. PubMed ID: 35251294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]